Fig 1: The assessment of myrrh essential oil (50 and 100 mg/kg) administration for three weeks prior to renal ischemia/perfusion (I/R) through the renal function tests: (a) creatinine, (b) BUN, (c) uric acid, (d) LDL; renal injury biomarkers: (e) Kim-1, (f) NGAL, and (g) CysC. All values are expressed as mean ± SD. # indicates a statistically significant difference from the sham group, € indicates a statistically significant difference from the renal I/R group, and ¥ indicates a statistically significant difference from myrrh 50 mg/kg + renal I/R group (p < 0.05) using one-way ANOVA followed by Turkey’s post hoc test (n = 6).
Fig 2: Protective effect of Gal EO (50 or 100 mg/kg for 2 weeks) in Genta-associated AKI as reflected in renal function tests including serum level of Cr (a), uric acid (b), BUN (c), CysC (d), NGAL (e), and Kim-1 (f) as well as the urine albumin/creatinine (g). All values were stated as mean ± SD (n = 6). # signifies compared to the normal group; ∂ signifies compared to the Genta group; Φ signifies compared to Genta +Gal EO (50 mg/kg) group. Comparisons done using one-way ANOVA followed by the Tukey-Kramer post hoc test (p < 0.05).
Supplier Page from Abcam for Rat Cystatin C ELISA Kit